As of 2025-07-20, the Intrinsic Value of Shanghai Rongtai Health Technology Corp Ltd (603579.SS) is 15.86 CNY. This 603579.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 29.04 CNY, the upside of Shanghai Rongtai Health Technology Corp Ltd is -45.40%.
The range of the Intrinsic Value is 12.12 - 22.47 CNY
Based on its market price of 29.04 CNY and our intrinsic valuation, Shanghai Rongtai Health Technology Corp Ltd (603579.SS) is overvalued by 45.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 12.12 - 22.47 | 15.86 | -45.4% |
| DCF (Growth 10y) | 14.10 - 24.13 | 17.77 | -38.8% |
| DCF (EBITDA 5y) | 37.29 - 53.80 | 43.98 | 51.4% |
| DCF (EBITDA 10y) | 31.44 - 47.67 | 38.04 | 31.0% |
| Fair Value | 4.88 - 4.88 | 4.88 | -83.20% |
| P/E | 24.93 - 29.71 | 27.58 | -5.0% |
| EV/EBITDA | 14.24 - 23.73 | 18.87 | -35.0% |
| EPV | (0.82) - (0.24) | (0.53) | -101.8% |
| DDM - Stable | 6.12 - 13.57 | 9.85 | -66.1% |
| DDM - Multi | 16.38 - 25.64 | 19.80 | -31.8% |
| Market Cap (mil) | 5,151.70 |
| Beta | 1.32 |
| Outstanding shares (mil) | 177.40 |
| Enterprise Value (mil) | 5,734.87 |
| Market risk premium | 6.13% |
| Cost of Equity | 11.82% |
| Cost of Debt | 5.00% |
| WACC | 10.55% |